<code id='39AC394AF2'></code><style id='39AC394AF2'></style>
    • <acronym id='39AC394AF2'></acronym>
      <center id='39AC394AF2'><center id='39AC394AF2'><tfoot id='39AC394AF2'></tfoot></center><abbr id='39AC394AF2'><dir id='39AC394AF2'><tfoot id='39AC394AF2'></tfoot><noframes id='39AC394AF2'>

    • <optgroup id='39AC394AF2'><strike id='39AC394AF2'><sup id='39AC394AF2'></sup></strike><code id='39AC394AF2'></code></optgroup>
        1. <b id='39AC394AF2'><label id='39AC394AF2'><select id='39AC394AF2'><dt id='39AC394AF2'><span id='39AC394AF2'></span></dt></select></label></b><u id='39AC394AF2'></u>
          <i id='39AC394AF2'><strike id='39AC394AF2'><tt id='39AC394AF2'><pre id='39AC394AF2'></pre></tt></strike></i>

          Home / comprehensive / leisure time

          leisure time


          leisure time

          author:fashion    Page View:76
          Cholesterol
          APStock

          Verve Therapeutics said Sunday that the first 10 people to receive a one-time treatment powered by a form of CRISPR called base editing showed reductions in bad cholesterol levels — study results that are preliminary but signal the potential for gene-editing treatments to benefit people with an inherited type of cardiovascular disease.

          Three of the study participants treated with potentially therapeutic doses of the Verve drug, called VERVE-101, showed  reductions in LDL-C levels of 39%, 48%, and 55%, respectively. The latter patient’s decline in so-called “bad” cholesterol was maintained for six months.

          advertisement

          The Verve-101 study results were presented at the American Heart Association conference and are the first data in patients from a therapy that uses base editing to change individual letters of DNA. Verve licensed the base-editing technology from Beam Therapeutics.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In